Inhibrx Biosciences, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mark Paul Lappe
- Full Time Employees
- 156
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 11025 North Torrey Pines Road La Jolla CA United States of America 92037
- IPO Date
- Jun 4, 2024
- CIK
- 0002007919
- Website
- inhibrx.com
- Similar Companies
- Business
- Inhibrx Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, concentrating on the advancement of biological therapeutics intended for individuals facing life-threatening illnesses. The company was established in 2024, following a strategic spin-off that allowed its oncology and rare disease assets, distinct from INBRX-101, to continue independent development after the acquisition of Inhibrx, Inc. by Sanofi. Its development pipeline features ozekibart (INBRX-109), a precisely engineered tetravalent death receptor 5 (DR5) agonist, which recently reported positive topline data from its registrational Phase 2 study for the treatment of unresectable or metastatic conventional chondrosarcoma, with a Biologics License Application planned for the second quarter of 2026. Additional investigations for INBRX-109 include Phase 1 trials for Ewing sarcoma and colorectal cancer. Also in its pipeline is INBRX-106, a novel hexavalent OX40 agonist, currently undergoing a seamless Phase 2/3 randomized study in combination with pembrolizumab for first-line recurrent or metastatic head and neck squamous cell carcinoma, alongside other solid tumor evaluations in earlier phase trials. Leveraging proprietary protein engineering platforms, Inhibrx Biosciences focuses on creating multivalent therapeutic candidates designed to optimize target-specific agonist functions. The company is headquartered in La Jolla, California.
Inhibrx Reports First Quarter 2026 Financial Results
Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study
Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Receives $150.00 Consensus Target Price from Analysts
SG Americas Securities LLC Invests $1.27 Million in Inhibrx Biosciences, Inc. $INBX
Contrasting CollPlant Biotechnologies (NASDAQ:CLGN) and Inhibrx Biosciences (NASDAQ:INBX)
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
7,388 Shares in Inhibrx Biosciences, Inc. $INBX Acquired by Dynamic Technology Lab Private Ltd
Inhibrx Announces Participation in Upcoming Scientific Conference
Inhibrx Biosciences, Inc. $INBX Shares Sold by Credit Industriel ET Commercial
Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too
Why Inhibrx's Recent Strength May Not Be Built to Last